Ignite Creation Date:
2025-12-24 @ 4:41 PM
Ignite Modification Date:
2026-06-14 @ 4:11 PM
Study NCT ID:
NCT05288166
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-27
First Post:
2022-03-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Sponsor:
Eli Lilly and Company
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Prostatic Neoplasms | View |
| None | Neoplasm Metastasis | View |
| None | Urogenital Neoplasms | View |
| None | Physiological Effects of Drugs | View |
| None | Antineoplastic Agents | View |
| None | Antineoplastic Agents, Hormonal | View |
| None | Androgens | View |
| None | Hormones | View |
| None | Hormones, Hormone Substitutes, and Hormone Antagonists | View |
| None | Abiraterone Acetate | View |
| None | Steroid Synthesis Inhibitors | View |
| None | Cytochrome P-450 | View |
| None | Enzyme Inhibitors | View |
| None | Prednisone | View |
| None | Prednisolone | View |
| None | Cyclin-Dependent Kinase 4 | View |
| None | Cyclin-Dependent Kinase 6 | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Metastatic Hormone Sensitive Prostate Cancer | View |
| None | mHSPC | View |
| None | Stage IV Prostate Cancer | View |
| None | Recurrent Prostate Cancer | View |
| None | De Novo Metastatic Prostate Cancer | View |
| None | High-Risk | View |
| None | Visceral metastasis | View |
| None | Cyclin-Dependent Kinase 4 (CDK4) | View |
| None | Cyclin-Dependent Kinase 6 (CDK6) | View |
| None | CDK4 | View |
| None | CDK6 | View |
| None | CDK4/6 | View |